Palo Alto, California, and Needham, Massachusetts – June 4, 2024 – Bitterroot Bio, a pioneering biotechnology company focused on developing innovative medicines in the field of cardio-immunology, today announced the appointment of Georgette Verdin as Chief People Officer and Sherwin Chen as Chief Legal Officer and Corporate Secretary. “I am thrilled to welcome Georgette and […]

Palo Alto, California and Melbourne, Australia – April 29, 2024 – Bitterroot Bio, a leader in developing innovative medicines in the field of cardio-immunology, today announced that the first human participants have been dosed in a Phase 1 study of BRB-002 in healthy volunteers. BRB-002 is a novel protein therapy targeting CD47 that is being

Collaboration aims to discover novel bispecific proteins targeting immune modulators and inflammatory pathways implicated in cardiovascular disease Palo Alto, California, and Zhuhai, China – February 26, 2024 – Bitterroot Bio, a leader in innovative treatments for cardiovascular diseases, and Biotheus, a pioneer in monoclonal and multi-specific antibody design, today announced a multi-year research collaboration agreement.

PALO ALTO, Calif. – Bitterroot Bio, a biotechnology company focused on developing novel immunotherapies in cardiovascular disease, has been selected to present research at the upcoming American Heart Association Scientific Sessions conference, which will take place from November 11-13, 2023 at the Pennsylvania Convention Center in Philadelphia, PA. The abstract, titled “Blockade of CD47 Using